title: Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management.
abstract: BACKGROUND
  B-type natriuretic peptide is useful to diagnose heart failure. We determined whether the use of serial B-type natriuretic peptide measurements to guide treatment improves the outcome in patients with acute heart failure.
  
  
  RESULTS
  We conducted a randomized controlled trial of patients with acute heart failure in 10 academic and community emergency departments. The experimental group received serial B-type natriuretic peptide testing (at 3, 6, 9, and 12 hours then daily). The control group received usual care. Our outcomes were hospital length of stay, 30-day readmission rate, and all-cause mortality. There were 219 controls and 228 experimental patients. Mean age was 64 years, 49% were women, 58% were blacks, and 34% were whites. Groups were similar in baseline characteristics. Comparing the serial testing with the control group, there was no difference in length of stay (6.5 days [95% CI, 5.2 to 7.9] versus 6.5 days [95% CI, 5.6 to 7.3]; difference, 0.1 [95% CI, -1.7 to 1.5]), in-hospital mortality (2.2% [95% CI, 0.9 to 5.0] versus controls, 3.2% [95% CI, 1.6 to 6.5]; difference, 1.0% [95% CI, -2.3 to 4.5]), 30-day mortality (3.7% [95% CI, 1.8 to 7.5] versus 5.5% [95% CI, 3.0 to 9.8]; difference, 1.8% [95% CI, -2.8 to 6.5]), or hospital revisit rate (20.2% [95% CI, 15.0 to 26.6] versus 23.7% [95% CI, 18.0 to 30.6]; difference, 3.5% [95% CI, -5.1 to 12.1]).
  
  
  CONCLUSIONS
  In this study of 447 patients hospitalized for suspected heart failure, we were unable to demonstrate a benefit of serial testing with B-type natriuretic peptide in terms of hospital length of stay, mortality, or readmission rate.
authors.affiliation: Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, USA. adam.singer@stonybrook.edu
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Singer
authors.forename: Robert H
authors.initials: RH
authors.lastname: Birkhahn
authors.forename: David
authors.initials: D
authors.lastname: Guss
authors.forename: Abhinav
authors.initials: A
authors.lastname: Chandra
authors.forename: Chadwick D
authors.initials: CD
authors.lastname: Miller
authors.forename: Brian
authors.initials: B
authors.lastname: Tiffany
authors.forename: Phillip
authors.initials: P
authors.lastname: Levy
authors.forename: Robert
authors.initials: R
authors.lastname: Dunne
authors.forename: Aveh
authors.initials: A
authors.lastname: Bastani
authors.forename: Henry C
authors.initials: HC
authors.lastname: Thode
authors.forename: Judd E
authors.initials: JE
authors.lastname: Hollander
mesh_terms: D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis / Q000401:mortality*; D017052:Hospital Mortality; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010359:Patient Readmission; D011237:Predictive Value of Tests
chemical_list: D020097:Natriuretic Peptide, Brain